Page 127 - Haematologica3

AI diseases
1 male
2 female 3 male 4 male
5 male 6 male
7 female 8 female 9 male 10 female
11 male 12 male 13 male 14 male
1 male 2 male 3 male
4 male
5 male
6 male 1 male
2 male
3 female 4 male
1 male
Hematologic malignancy
M. Sjögren Sarcoidosis PSC
B-CLL
B-CLL B-CLL, AIHA and MN
PB Skin LN, spleen, BM
20
46
21 CD
Primary C-CD30+ T-LPD PTCL, NOS
54 43 46
81 62 78
59
75
75
70 MN
71
46 78
26
Skin
LN, spleen, liver LN, spleen, bone Skin
LN, liver
LN
Skin Spleen, BM, liver
LN
Small bowel, kidneys, pancreas, heart
LN, pelvic cavity, skin Nasopharynx
Azathioprine IA Adalimumab
T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies
Table 1. Patient characteristics.
Primary disorder Sex
Age at Dx
23
Disorder defined
CD
Location lymphoma
Kidney
Histologic subtype
Precursor T-LBL
Staging* Prior IS drugs or chemotherapy
IE Prednisolone
Period given
NR
>2y 1-2 y
NR >2y NR >2y NR >2y 1-2 y >2y >2y >2y 1-2 y 6-12 m >2y 1-2 y
>2y
NR
NR NR NR NR 1-2 y 6-12 m NR NR
3-6 m 3-6 m 3-6 m 6-12 m > 2 y <3 m 3-6 m 3-6 m NR NR NR
>2y >2y >2y >2y >2y >2y >2y
Interval start IST- Dx (m)
NR
NR NR
NR 44 NR 210 NR NR NR NR 173 NR 18 6 60 13
NR
92
NR NR NR NR 21 10 NR 143
13 13 13 NR 165 5
5
5 NR NR NR
367 367 367 367 95 315 315
CD and PSC
CD Liver HSTCL IV Azathioprine
39 CD 43 CD
36 CD 40 RA 52 RA 75 RA 70 PMR
Precursor T-LBL PTCL, NOS
IV Azathioprine Prednisolone III Azathioprine IV Prednisolone
Azathioprine Infliximab Adalimumab
II Azathioprine II Methotrexate IA Etanercept IV Methotrexate IV Prednisolone IA Prednisolone
III NR
II Prednisolone
IV Chlorambucil IA NR
IV Chlorambucil
Prednisolon Cyclophosphamide Rituximab PI3K-inhibitor
IV Cyclophosphamide Prednisolone
CT, multiple courses
IV Cyclophosphamide Rituximab
Fludarabine Peginterferon III Chlorambucil
IV MMF Prednisolone
Tacrolimus Chlorambucil Cyclophosphamide Prednisolone
IIIE Prednisolone MS
Azathioprine Tacrolimus IV Tacrolimus
IV Prednisolone Azathioprine
II None
ALCL, ALK- ENKL, nasal type Mycosis Fungoides AITL
AITL
Mycosis Fungoides AITL
ALCL, ALK+ (small cell variant) T-PLL
Primary C-CD30+ T-LPD PTCL, NOS
Organ transplantation
BM, spleen, liver
LN, lung
Spleen Medulla oblongata, pons
Small bowel
LN, bone marrow
Small bowel T-NHL, unclassifiable
LN, lung ALCL, ALK-
Multiple myeloma and ASCT
Mantle cell lymphoma
B-CLL Kidney Tx,
Kidney Tx
Liver Tx Kidney tx
HIV
PTCL, NOS
ALCL, ALK-
PTCL, NOS
Clonal T-cell population in liquor, CNS lymphoma at imaging
ALCL, ALK-
HIV
EBV+ PTCL, NOS
*For cutaneous lymphomas the tumor-node-metastasis-blood (TNMB) system was used. All other lymphomas were staged by the Ann Arbor staging system. AI: autoimmune; AIHA: autoimmune hemolytic anemia; AITL: angioimmunoblastic T-cell lymphoma; ALCL: T-cell anaplastic large cell lymphoma; ALK: anaplastic lymphoma kinase; ASCT: autol- ogous stem cell transplant; B-CLL: B-cell chronic lymphatic leukemia; BM: bone marrow; CT: chemotherapy; CD: Crohn’s disease; Dx: diagnosis; EBV: Epstein-Barr virus; ENKL: extra- nodal NK/T-cell lymphoma; HIV: human immunodeficiency virus; HSTCL: hepatosplenic T-cell lymphoma; IQR: interquartile range; IS(T): immunosuppressive (therapy); LN: lymph nodes; MMF: mycophenolate mofetil; MS: mycophenolate sodium; MN: membranous nephropathy; NR: not recorded/retraceable; PB: peripheral blood; PMR: polymyalgia rheumat- ica;Primary C-CD30+ T-LPD:primary cutaneous CD30+ T-cell lymphoproliferative disease;PSC:primary sclerosing cholangitis;PTCL,NOS:peripheralT-cell lymphoma,not otherwise specified; RA: rheumatoid arthritis; T-LBL: T-cell lymphoblastic lymphoma; T-PLL: T-cell prolymphocytic leukemia; T-NHL: T-cell non-Hodgkin lymphoma; Tx: transplantation.
haematologica | 2018; 103(3)
487